Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)

NCT04231981 ↗

Phase 2 Completed 18 enrolled MedSIR Incyte Biosciences International Sàrl · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, single-arm, phase II clinical trial to evaluate the efficacy and safety of INCMGA00012 in Advanced Penile Squamous Cell Carcinoma

Timeline

Start: 2020-04-28
Primary completion: 2022-02-15
Completion: 2022-08-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Retifanlimab	Monoclonal antibody	500 mg	Intravenous

Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)

Summary

Timeline

Drugs

Indications